BioCryst Reports Inducement Grants Under Nasdaq Listing
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
Source: globenewswire.com
Page 3 - John Bluth News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from John Bluth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In John Bluth Today - Breaking & Trending Today
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the BioCryst Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference to Mr.
Source: insidermonkey.com
BioCryst Pharmaceuticals (BCRX) Q2 2023 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2023.
Source: fool.com
BioCryst to Report Second Quarter 2023 Financial Results on
RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
Source: globenewswire.com
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO® (berotralstat) in Turkey. “We continue our mission to make ORLADEYO available to as many patients living with hereditary angioedema around the world as possible by partnering with companies that have deep expertise in commercializing rare disease therapies. We are pleased t
Source: yahoo.com